Genetic Engineering & Biotechnology NewsCRISPR/Cas9 Fitted with Ultrasound-Powered PropellerGenetic Engineering & Biotechnology NewsOnce inside the cell, the nanopropeller falls apart and frees its cargo: a gene-editing complex consisting of the … Continue reading
CNBCHe sold his last company for $3.4 billion — now Lars Dalgaard will teach tech leaders to empathizeCNBCLars Dalgaard, who sold SuccessFactors to SAP for $3.4 billion in 2011 before going into venture capital, is stepping down from his general partne… Continue reading
Endpoints NewsCSO Bill Lundberg transitions to advisor role at CRISPR Therapeutics; Prothena loses CMO Sarah Noonberg; Sanofi …Endpoints NewsWrapping a three-year run marked by the first clinical trial applications for CRISPR-based therapies, Bill Lu… Continue reading
Seeking Alpha |
Mergers And Acquisitions: Is There A Pending Catalyst For Crispr Therapeutics?
Seeking Alpha The aforementioned statement suggested that there’s a favorable chance that Gilead is sizing up the following leading gene editing innovators for acquisition: CRISPR Therapeutics (NASDAQ:CRSP), Editas Medicine (NASDAQ:EDIT), Intellia Therapeutics … |
|
BMS Immunotherapy Combo Study Backs FoundationOne CDx Tumor Mutational Burden Indication
GenomeWeb NEW YORK (GenomeWeb) – A study evaluating the combination of Bristol-Myers Squibb’s immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) may support regulatory approval for the regimen as an option for lung cancer patients with a large number of … Phase 3 CheckMate-227 Trial Met Co-Primary Endpoint of PFS in NSCLCAJMC.com Managed Markets Network |
FierceBiotech |
CRISPR CSO departs as Celgene continues to sell stock
FierceBiotech In the absence of Lundberg, Tony Ho, M.D., will oversee CRISPR’s R&D activities. CRISPR appointed Ho, who previously worked at AstraZeneca and Merck, as its head of R&D in August. Ho inherits a broad preclinical pipeline of ex vivo and in vivo CRISPR … CRISPR Therapeutics Announces Transition of Bill Lundberg, MDGlobeNewswire (press release) Why Crispr Therapeutics AG Stock Bolted Higher in JanuaryMotley Fool Analysts Layout Best- And Worst-Case Scenarios: CRISPR Therapeutics AG (CRSP), Diodes Incorporated (DIOD)Post Analyst The Ledger Gazette –StockNewsTimes –StockNewsGazette all 27 news articles » |